Analyses Adjusting for Selective Crossover Show Improved Overall Survival with Decitabine Compared with Treatment Choice in DACO-016 Phase III TrialJörg Tomeczkowski, Christoph Tapprich, Andreas Güntert et al.|Value in Health|2013Cited by 0